Unum Therapeutics (UMRX) Issues Earnings Results

Unum Therapeutics (NASDAQ:UMRX) released its earnings results on Monday. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.34), Bloomberg Earnings reports.

Unum Therapeutics opened at $10.56 on Tuesday, MarketBeat Ratings reports. Unum Therapeutics has a 1 year low of $10.43 and a 1 year high of $10.65.

In related news, major shareholder Venture Fund Ix L.P. Atlas acquired 94,052 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The stock was bought at an average price of $12.00 per share, for a total transaction of $1,128,624.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Liam Ratcliffe acquired 550,000 shares of the firm’s stock in a transaction dated Tuesday, April 3rd. The stock was bought at an average price of $12.00 per share, with a total value of $6,600,000.00. The disclosure for this purchase can be found here.

A number of equities analysts have issued reports on UMRX shares. Morgan Stanley started coverage on Unum Therapeutics in a report on Monday, April 23rd. They set an “overweight” rating and a $20.00 target price for the company. Wedbush started coverage on Unum Therapeutics in a report on Monday, April 23rd. They set an “outperform” rating and a $18.00 target price for the company. SunTrust Banks started coverage on Unum Therapeutics in a report on Monday, April 23rd. They set a “buy” rating and a $21.00 target price for the company. Finally, Cowen started coverage on Unum Therapeutics in a report on Monday, April 23rd. They set a “market perform” rating for the company.

About Unum Therapeutics

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply